ACHIEVE LIFE SCIENCES, INC. (ACHV) - Dilution Analysis

10-Q filing | 102.7M shares outstanding

S-3 filing: This filing registers the potential resale of up to 99,037,138 shares of common stock by selling stockholders, including shares issued under a Purchase Agreement and shares underlying pre-funded and common warrants.

8-K filing: Achieve Life Sciences, Inc. entered into a securities purchase agreement to sell and issue shares of common stock and warrants in a private placement. ($180.0M proceeds)

10-K filing | 53.2M shares outstanding

S-3 filing: Achieve Life Sciences, Inc. may offer up to $300,000,000 aggregate amount of shares of common stock or preferred stock, debt securities, warrants, subscription rights and/or units in one or more offerings.

10-Q filing | 51.1M shares outstanding

8-K filing: Achieve Life Sciences, Inc. entered into an underwriting agreement to issue and sell 15,000,000 shares of common stock and accompanying warrants at a price of $3.00 per share and warrant. ($45.0M proceeds)

10-Q filing | 34.7M shares outstanding

10-K filing | 32.1M shares outstanding

POS AM filing: This is a POS AM filing to deregister any and all securities that remain unsold under the Registration Statement No. 333-272641 on Form S-3 as of November 7, 2024.

S-3 filing: Registration for potential offer and sale from time to time of up to an aggregate of 3,488,727 shares of common stock by the selling stockholders upon conversion of debt.

10-Q filing | 34.4M shares outstanding

10-Q filing | 34.3M shares outstanding

S-3 filing: The company is filing a shelf registration statement on Form S-3 to offer up to $200,000,000 aggregate amount of shares of our common stock or preferred stock, debt securities, warrants to purchase our common stock, preferred stock or debt securities, subscription rights to purchase our common stock, preferred stock or debt securities and/or units consisting of some or all of these securities, in any combination, together or separately, in one or more offerings.

10-Q filing | 34.3M shares outstanding

S-3 filing: This prospectus relates to the registration for potential offer and sale from time to time of up to 13,086,151 shares of our common stock by the selling stockholders.

10-K filing | 34.3M shares outstanding

8-K filing: Achieve Life Sciences, Inc. entered into a securities purchase agreement for the sale of up to 13,086,151 shares of common stock at a price of $4.585 per share and a concurrent private placement of warrants.

10-Q filing | 21.1M shares outstanding

10-Q filing | 19.0M shares outstanding

S-3 filing: This prospectus relates to the registration for potential offer and sale from time to time of up to 1,986,611 shares of our common stock by the selling stockholders.

8-K filing: Achieve Life Sciences, Inc. entered into a securities purchase agreement for the sale of 3,000,000 shares of common stock at $5.50 per share, resulting in gross proceeds of approximately $16.5 million. ($16.5M proceeds)

10-Q filing | 17.9M shares outstanding

10-K filing | 17.9M shares outstanding

S-3 filing: The filing registers 12,279,423 shares of common stock for potential offer and sale by selling stockholders, including outstanding shares and shares issuable upon exercise of warrants.

8-K filing: Achieve Life Sciences, Inc. completed a private placement offering 4,093,141 units, each consisting of two shares of common stock and a warrant to purchase one share of common stock, at $4.625 per unit, for gross proceeds of approximately $18.9 million. ($37.8M proceeds)

10-Q filing | 9.7M shares outstanding

10-Q filing | 9.6M shares outstanding

10-Q filing | 9.7M shares outstanding

10-K filing | 9.5M shares outstanding

S-3 filing: The filing is an S-3 form for Achillion Pharmaceuticals, indicating a shelf registration to offer common stock, preferred stock, debt securities, warrants, subscription rights and units for an aggregate amount of up to $100,000,000.

10-Q filing | 9.5M shares outstanding

10-Q filing | 9.5M shares outstanding

8-K filing: Achieve Life Sciences, Inc. entered into an underwriting agreement with Oppenheimer & Co., Inc., as representative of the underwriters, to issue and sell 2,857,143 shares of its common stock at a public offering price of $7.00 per share. ($20.0M proceeds)

10-Q filing | 6.2M shares outstanding

10-K filing | 6.1M shares outstanding

S-1/A filing: This is an S-1/A filing detailing other expenses of issuance and distribution related to a common stock offering.

10-Q filing | 3.6M shares outstanding

10-Q filing | 3.6M shares outstanding

8-K filing: Achieve Life Sciences, Inc. entered into an underwriting agreement with Lake Street Capital Markets, LLC, to issue and sell 476,187 shares of common stock and pre-funded warrants to purchase 142,857 shares of common stock at $10.50 and $10.499 respectively.

8-K filing: Achieve Life Sciences, Inc. entered into a securities purchase agreement for the sale of 14,634,146 shares of common stock at $0.41 per share, resulting in gross proceeds of approximately $6.0 million. ($6.0M proceeds)

S-1 filing: Registration for potential offer and sale of up to 10,332,801 shares of common stock by selling stockholders.

10-Q filing | 37.5M shares outstanding

10-K filing | 31.4M shares outstanding